Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00327470
Status:
TERMINATED
Last Update Posted:
2012-04-04
First Post:
2006-05-17
Brief Title:
An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A 102-Week Open Label Multicenter Trial To Investigate The Efficacy Of Macugen For The Preservation Of Visual Function In Subjects With Neovascular Age-Related Macular Degeneration AMD And To Assess The Benefit Of Treating Early Choroidal Neovascularization CNV
Status:
TERMINATED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
See termination reason in detailed description
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PERSPECTIVES
Brief Summary:
The purpose of this study is to determine the benefits of treating subjects with neovascular age-related macular degeneration AMD at an earlier stage of choroidal neovascularization CNV as compared to those with established CNV Additionally the study would like to determine the efficacy of Macugen in preserving visual function in those subjects having CNV secondary to neovascular AMD
Detailed Description:
A decision was made by the sponsor 08 May 2009 to terminate this study early the study had achieved the primary objective prior to termination This study was not terminated due to safety reasons
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None